KR20190039769A - 호산구성 식도염의 치료 방법 - Google Patents

호산구성 식도염의 치료 방법 Download PDF

Info

Publication number
KR20190039769A
KR20190039769A KR1020197007310A KR20197007310A KR20190039769A KR 20190039769 A KR20190039769 A KR 20190039769A KR 1020197007310 A KR1020197007310 A KR 1020197007310A KR 20197007310 A KR20197007310 A KR 20197007310A KR 20190039769 A KR20190039769 A KR 20190039769A
Authority
KR
South Korea
Prior art keywords
patient
corticosteroid
oral
week
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197007310A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 멜처
게일 코머
Original Assignee
아데어 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아데어 파마슈티컬스 인코포레이티드 filed Critical 아데어 파마슈티컬스 인코포레이티드
Priority to KR1020217023832A priority Critical patent/KR20210095973A/ko
Publication of KR20190039769A publication Critical patent/KR20190039769A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electronic Switches (AREA)
KR1020197007310A 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법 Ceased KR20190039769A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217023832A KR20210095973A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376703P 2016-08-18 2016-08-18
US62/376,703 2016-08-18
US201762461317P 2017-02-21 2017-02-21
US62/461,317 2017-02-21
US201762489292P 2017-04-24 2017-04-24
US62/489,292 2017-04-24
PCT/US2017/047474 WO2018035393A1 (en) 2016-08-18 2017-08-18 Methods of treating eosinophilic esophagitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217023832A Division KR20210095973A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190039769A true KR20190039769A (ko) 2019-04-15

Family

ID=61197039

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217023832A Ceased KR20210095973A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법
KR1020237040942A Ceased KR20230167146A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법
KR1020197007310A Ceased KR20190039769A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020217023832A Ceased KR20210095973A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법
KR1020237040942A Ceased KR20230167146A (ko) 2016-08-18 2017-08-18 호산구성 식도염의 치료 방법

Country Status (11)

Country Link
US (7) US10105315B2 (enExample)
EP (1) EP3500264A4 (enExample)
JP (3) JP6929934B2 (enExample)
KR (3) KR20210095973A (enExample)
AU (2) AU2017312660B2 (enExample)
CA (1) CA3034264A1 (enExample)
NZ (1) NZ750754A (enExample)
RU (1) RU2766577C2 (enExample)
TW (2) TWI777515B (enExample)
UY (1) UY37370A (enExample)
WO (1) WO2018035393A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
SG10201704847WA (en) 2009-10-01 2017-07-28 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
NZ630178A (en) 2012-09-07 2017-06-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11672959B2 (en) * 2019-01-18 2023-06-13 Intersect Ent, Inc. Expandable member systems and methods for drug delivery
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
EA202193001A1 (ru) 2019-05-02 2022-02-08 ИНТЕРСЕКТ ИЭнТи ИНТЕРНЭШНЛ ГМБХ Устройство баллонной дилатации
KR20220042217A (ko) 2019-08-05 2022-04-04 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11321488B2 (en) 2019-09-20 2022-05-03 International Business Machines Corporation Policy driven data movement
US11327665B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Managing data on volumes
US11328089B2 (en) 2019-09-20 2022-05-10 International Business Machines Corporation Built-in legal framework file management
US11106813B2 (en) * 2019-09-20 2021-08-31 International Business Machines Corporation Credentials for consent based file access
US11443056B2 (en) 2019-09-20 2022-09-13 International Business Machines Corporation File access restrictions enforcement
US11188680B2 (en) 2019-09-20 2021-11-30 International Business Machines Corporation Creating research study corpus
US20220347189A1 (en) * 2019-10-01 2022-11-03 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
US11075010B1 (en) * 2020-03-19 2021-07-27 Insight RX, Inc. Pharmacology model optimization based on distributed data acquisition
WO2021216917A1 (en) * 2020-04-22 2021-10-28 Topical Sinus Therapeutics, Inc. Targeted administration to the oropharynx of viscous or dry powder fluticasone propionate and related corticosteroids for the treatment of eosinophilic esophagitis (eoe)
CN115768516A (zh) * 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
CN117295501A (zh) * 2021-04-20 2023-12-26 埃洛迪制药公司 治疗食管狭窄的方法
WO2022232104A1 (en) * 2021-04-26 2022-11-03 Praxis Precision Medicines, Inc. Methods of treatment with neuroactive steroids
JP2025526506A (ja) * 2022-07-28 2025-08-13 ザ メディカル カレッジ オブ ウィスコンシン インク 逆流症の治療のための持続放出経口ホスアンプレナビル製剤
WO2025128792A1 (en) * 2023-12-13 2025-06-19 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and depleting mast cell

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
WO1997047287A1 (en) 1996-06-14 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
IL145983A0 (en) 1999-04-23 2002-07-25 Leo Pharm Prod Ltd Pharmaceutical composition for dermal use, comprising a corticosteroid and a vitamin d or an analogue thereof
EP1143930B8 (en) 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
AU2002240755B2 (en) 2001-03-13 2007-07-05 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR20060079257A (ko) 2001-05-10 2006-07-05 아스텔라스세이야쿠 가부시키가이샤 구강내 신속 붕괴성 정제 및 이의 제조방법
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
AU2003222310B2 (en) 2002-05-03 2009-04-09 Janssen Pharmaceutica N.V. Polymeric microemulsions
AU2003270357A1 (en) 2002-09-06 2004-03-29 Microbia, Inc. Inhibitors of fungal invasion
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4475233B2 (ja) 2003-01-21 2010-06-09 日本新薬株式会社 口腔内速崩性錠剤
NZ541167A (en) 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
DE602005014227D1 (de) 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1634586B1 (en) 2004-09-09 2007-02-14 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Fast water-dispersible domperidone tablets
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
US8048449B2 (en) 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
WO2008128115A2 (en) 2007-04-13 2008-10-23 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations
US20150231156A1 (en) * 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
US20090123551A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US9050368B2 (en) 2007-11-13 2015-06-09 Meritage Pharma, Inc. Corticosteroid compositions
LT3354276T (lt) 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
MX2010006326A (es) 2007-12-10 2010-10-04 Eurand Inc Comprimidos de desintegracion oral que comprenden difenhidramina.
US20090169620A1 (en) 2007-12-21 2009-07-02 Venkatesh Gopi M Orally disintegrating tablet compositions of temazepam
JP2009173552A (ja) 2008-01-21 2009-08-06 Lion Corp 胃腸薬
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
DK2151235T3 (da) 2008-07-21 2011-04-11 Falk Pharma Gmbh Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
WO2010017433A2 (en) 2008-08-08 2010-02-11 Mcneil-Ppc, Inc. Use of sucralose as a granulating agent
HRP20201231T1 (hr) 2008-08-20 2020-12-11 The Regents Of The University Of California Kortikosteroidi, namijenjeni liječenju upalnih bolesti gastrointestinalnog sustava
RU2011134040A (ru) 2009-01-15 2013-02-20 Нестек С.А. Способы диагностики и лечения дисфагии
US20120128764A1 (en) 2009-02-23 2012-05-24 Aptalis Pharmatech, Inc. Controlled-release compositions comprising a proton pump inhibitor
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
JP5879265B2 (ja) 2009-09-07 2016-03-08 デベヴェ・テクノロジーズ 好酸球性食道炎を処置する方法
SG10201704847WA (en) 2009-10-01 2017-07-28 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
JP5854476B2 (ja) 2009-11-30 2016-02-09 アデア ファーマスーティカルズ，インコーポレイテッド 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
ES2894936T3 (es) * 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
JP5977255B2 (ja) 2011-01-18 2016-08-24 ユニバーシティー ヘルス ネットワーク 嚥下障害検出装置及びその作動方法
US10238331B2 (en) 2011-01-28 2019-03-26 Nestec S.A. Apparatuses and methods for diagnosing swallowing dysfunction
WO2013088109A1 (en) * 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2014016754A2 (en) 2012-07-26 2014-01-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
FI2886108T4 (fi) 2013-12-23 2023-02-22 Optimoitu farmaseuttinen koostumus ruokatorven tulehduksellisten muutosten hoitoon
US10294517B2 (en) 2014-03-17 2019-05-21 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) * 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN112334189A (zh) 2018-02-21 2021-02-05 美国阿代尔制药公司 管理嗜酸细胞性食管炎的方法
US20220347189A1 (en) 2019-10-01 2022-11-03 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
CN117295501A (zh) 2021-04-20 2023-12-26 埃洛迪制药公司 治疗食管狭窄的方法

Also Published As

Publication number Publication date
TW202206079A (zh) 2022-02-16
TW201808304A (zh) 2018-03-16
US20180133145A1 (en) 2018-05-17
JP6929934B2 (ja) 2021-09-01
WO2018035393A1 (en) 2018-02-22
US20210275438A1 (en) 2021-09-09
CA3034264A1 (en) 2018-02-22
JP2021178866A (ja) 2021-11-18
UY37370A (es) 2018-01-02
AU2023233115A1 (en) 2023-10-12
KR20210095973A (ko) 2021-08-03
US20230414498A1 (en) 2023-12-28
KR20230167146A (ko) 2023-12-07
US11684571B2 (en) 2023-06-27
JP7526143B2 (ja) 2024-07-31
US10105315B2 (en) 2018-10-23
US20250170057A1 (en) 2025-05-29
TWI728172B (zh) 2021-05-21
US20210346278A1 (en) 2021-11-11
US11896710B2 (en) 2024-02-13
JP2024164004A (ja) 2024-11-26
US11026887B2 (en) 2021-06-08
NZ750754A (en) 2023-02-24
RU2019105805A3 (enExample) 2020-11-13
RU2019105805A (ru) 2020-09-18
US20190008760A1 (en) 2019-01-10
US12059494B2 (en) 2024-08-13
JP2019528272A (ja) 2019-10-10
EP3500264A1 (en) 2019-06-26
EP3500264A4 (en) 2020-04-29
US20200368147A1 (en) 2020-11-26
AU2017312660B2 (en) 2023-06-29
TWI777515B (zh) 2022-09-11
RU2766577C2 (ru) 2022-03-15
AU2017312660A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
US12059494B2 (en) Methods of treating eosinophilic esophagitis
US20250255884A1 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
TWI871342B (zh) 非鎮靜之右美托咪啶(dexmedetomidine)治療方案
US20250302808A1 (en) Dexmedetomidine treatment regimens
CN116801863A (zh) 右美托咪定治疗方案
NZ790981A (en) Methods of treating eosinophilic esophagitis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200619

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200619

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200814

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200814

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201228

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201014

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200619

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210225

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210527

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210426

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210225

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201228

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201014

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200814

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200619

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210727